Fig. 2
From: Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis
Effects of anti-IL-23p19 treatment on IL-17 and antibody levels in EAMG. ELISA analysis of the serum levels of IL-17 (4 weeks after treatment) (A), total anti-T-AChR antibodies (B), anti-T-AChR IgG1 subtype antibodies (C) and anti-T-AChR IgG2b subtype antibodies (D) in CFA and EAMG mice. The levels of anti-T-AChR antibodies of subtypes IgG1 and IgG2 were normalized to the total IgG levels. Analyses were performed in duplicate on serum obtained after 2 weeks or 4 weeks of treatment. For each treatment time, data were obtained from 2 independent experiments (EAMG mice n ≥ 8 per group). Each point represents an individual mouse. P values were obtained with an ANOVA test. The P values are indicated as follows: * < 0.05; **0.0015; ***0.0002; ****0.0001